Messina, JP, et al.
Global distribution and prevalence of hepatitis C virus genotypes. Hepatology
2014; 61: 77–87.
Antonov, K, et al.
Predictors of sustained virological response (SVR) to pegylated interferon alpha (PEG-INF-a) and ribavirin (RBV) in patients with chronic hepatitis C infected with genotype 1. Journal of IMAB
2011; 17: 197–199.
Hoofnagle, JH, Seeff, LB. Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 2006; 355: 2444–2451.
Parruti, G, et al.
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48 h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research
2010; 88: 124–127.
Mirmomen, S, Alavian, SM. Treatment of HCV infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response. Hepatitis Monthly
2005; 5: 11–13.
Samuel, CE. Antiviral actions of interferons.
Clinical Microbiology Reviews
2001; 14: 778–809.
Lin, RJ, et al.
Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. Journal of Virology
2004; 78: 9285–9294.
Poordad, F, Reddy, KR, Martin, P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clinical Infectious Diseases
2008; 46: 78–84.
Martin-Carbonero, L, et al.
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Aids
2008; 22: 15–21.
Legrand-Abravanel, F, et al.
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology
2009; 81: 2029–2035.
Kamal, SM, et al.
Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut
2005; 54: 858–866.
Huang, CF, et al.
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Journal of Hepatology
2012; 56: 34–40.
Tanaka, Y, et al.
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics
2009; 41: 1105–1109.
Ge, D, et al.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature
2009; 461: 399–401.
Ferreira, CS, et al.
A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS ONE
2013; 8: e78142.
Di Marco, V, et al.
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood
2010; 116: 2875–2883.
Tabatabaei, SV, et al.
Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepatitis Monthly
2012; 12: 372.
Al-Kubaisy, WA, Habib, KTA. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. Eastern Mediterranean Health Journal
2006; 12: 204–210.
Samimi-Rad, K, et al.
Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. Journal of Medical Virology
2004; 74: 246–252.
Koshy, A, et al.
Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. Journal of Clinical Gastroenterology
2002; 35: 82–85.
Ohno, T, et al.
Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients. Archives of Virology
1996; 141: 1101–1113.
Suppiah, V, et al.
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics
2009; 41: 1100–1104.
Urban, TJ, et al.
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology
2010; 52: 1888–1896.
Rivero-Juarez, A, et al.
HCV viral decline at week 2 of peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. PLoS ONE
2014; 9: e99468.